Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Quercetin  COVID-19 treatment studies for Quercetin  C19 studies: Quercetin  Quercetin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 86% Improvement Relative Risk ICU admission 40% Time to discharge from.. 32% c19early.org/q Shohan et al. Quercetin for COVID-19 RCT LATE TREATMENT Is late treatment with quercetin beneficial for COVID-19? RCT 60 patients in Iran Faster recovery with quercetin (p=0.039) Shohan et al., European J. Pharmacology, doi:10.1016/j.ejphar.2021.1746158 Favors quercetin Favors control
The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial
Shohan et al., European Journal of Pharmacology, doi:10.1016/j.ejphar.2021.1746158
Shohan et al., The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A.., European Journal of Pharmacology, doi:10.1016/j.ejphar.2021.1746158
Dec 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small RCT with 60 severe hospitalized patients in Iran, 30 treated with quercetin, showing shorter time until discharge. All patients received remdesivir or favipiravir, and vitamin C, vitamin D, famotidine, zinc, dexamethasone, and magnesium (depending on serum levels). Quercetin 1000mg daily for 7 days. IRCT20200419047128N2.
risk of death, 85.7% lower, RR 0.14, p = 0.24, treatment 0 of 30 (0.0%), control 3 of 30 (10.0%), NNT 10.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of ICU admission, 40.0% lower, RR 0.60, p = 0.71, treatment 3 of 30 (10.0%), control 5 of 30 (16.7%), NNT 15.
time to discharge from end of intervention, 32.4% lower, relative time 0.68, p = 0.04, treatment 30, control 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shohan et al., 2 Dec 2021, Randomized Controlled Trial, Iran, peer-reviewed, mean age 50.9 (treatment) 52.7 (control), 8 authors, average treatment delay 7.8 days.
Contact: akhodadadi2@gmail.com, akhodadadi@ajums.ac.ir.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperQuercetinAll
Abstract: Journal Pre-proof The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial Mojtaba Shohan, Roohangiz Nashibi, Mohammad-Reza Mahmoudian-Sani, Farhad Abolnezhadian, Mehri Ghafourian, Seyed Mohammad Alavi, Asaad Sharhani, Ali Khodadadi PII: S0014-2999(21)00771-8 DOI: https://doi.org/10.1016/j.ejphar.2021.174615 Reference: EJP 174615 To appear in: European Journal of Pharmacology Received Date: 18 June 2021 Revised Date: 23 October 2021 Accepted Date: 1 November 2021 Please cite this article as: Shohan, M., Nashibi, R., Mahmoudian-Sani, M.-R., Abolnezhadian, F., Ghafourian, M., Alavi, S.M., Sharhani, A., Khodadadi, A., The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial, European Journal of Pharmacology (2022), doi: https://doi.org/10.1016/j.ejphar.2021.174615. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2021 Published by Elsevier B.V. Authorship contribution statement Mojtaba Shohan: Conceptualization, Methodology, Writing original draft, Writing – review and editing. Roohangiz Nashibi: Visualization, Supervision. Mohammad-Reza Mahmoudian-Sani: Methodology, Investigation. Farhad Abolnezhadian: Supervision. Mehri Ghafourian: Review and editing. Seyed Mohammad Alavi: Supervision. Asaad Sharhani: Formal analysis, Visualization. Ali Khodadadi: Jo ur na lP re -p ro of Supervision, Conceptualization, Funding acquisition. And The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial Mojtaba Shohan a,b , Roohangiz Nashibi c , Mohammad-Reza Mahmoudian-Sani d Farhad Abolnezhadian e , Mehri Ghafourian a , Seyed Mohammad Alavi c , Asaad Sharhani f , Ali Khodadadi a,g a Department of Immunology, School of M edicine, Ahvaz Jundishapur University of M edical Sciences, Ahvaz, Iran b Student Research Committee, Ahvaz Jundishapur University of M edical Sciences, Ahvaz, Iran of c Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of M edical ro Sciences, Ahvaz, Iran -p d Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of M edical re Sciences, Ahvaz, Iran lP e Department of Pediatrics, Abuzar children's hospital, Ahvaz Jundishapur University of M edical Sciences, Ahvaz, Iran f Department of Epidemiology and Biostatistics, School of public health, Ahvaz Jundishapur University of M edical Sciences , na Ahvaz, Iran Jo ur g Cancer Research Center, Ahvaz Jundishapur University of M edical Sciences, Ahvaz, Iran Corresponding author: Dr. Ali Khodadadi, Professor in Immunology Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran E-mail Address: akhodadadi2@gmail.com and..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit